Clinical Consultations™: Novel Therapeutic Targets in Neovascular Retinal Diseases – A Focus on the Roles of VEGF-C & D
This activity is supported by an educational grant from Opthea.
Overview
Release Date
September 30, 2024
Expiration Date
September 30, 2025
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Opthea.
Activity Overview
This Clinical ConsultationsTM is a video-based program in which a panel of experts discuss the treatment and management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), with a particular focus on investigational therapies with different mechanisms of action to target VEGF-C and VEGF-D. This engaging format is designed to help clinicians identify best practices in the management of neovascular retinal disease with an eye toward potential future opportunities to address today’s unmet needs.
Target Audience
This online educational activity is directed toward retina specialists, ophthalmologists, and other eyecare clinicians who may treat patients with neovascular retinal diseases.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the role of VEGF-C/D in the pathogenesis of nAMD and DME.
- Describe the mechanism of action of novel therapies that target VEGF C/D.
- Assess current evidence evaluating the role of VEGF-C/D inhibitors in the treatment of nAMD and DME.
- Identify patients appropriate for treatment with VEGF-C/D inhibitors based on clinical presentation and goals of therapy.
Faculty
Veeral Sheth, MD, MBA, FACS, FASRS
Partner and Director, Clinical Trials
University Retina
Oak Forest, IL
Disclosures: Speaker: Genentech, Iveric Bio;
Consultant: Apellis, EyePoint, Genentech, Iveric Bio, Janssen, Kriya Therapeutics, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Ollin Biosciences, Opthea, Regeneron, RevOpsis, Unity Biotechnology, Vial;
Contracted research: 4D Molecular Therapeutics, AbbVie, Adverum Biotechnologies, Alimera Sciences, Ashvattha Therapeutics, Astellas, Aviceda, Chengdu Kanghong, Eluminex Biosciences, Eyebiotech, EyePoint Pharmaceuticals, Genentech, Gyroscope Therapeutics, i-Lumen Scientific, Ionis, Iveric Bio, Janssen Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Oculus, Ocugen, OcuTerra, OliX Pharmaceuticals, Opthea, Outlook, Oxular, Oxurion, Perfuse Therapeutics, Recens Medical, Regeneron Pharmaceuticals, Regenxbio, Rezolute, Roche, SalutarisMD, Sam Chun Dang Pharm, Santen, Smilebiotek, Unity Biotechnology, Vanotech.
Dante Pieramici, MD
Managing Partner
California Retina Consultants
Bakersfield, CA
Disclosures: Grant/Research Support: 4DMT, Adverum, Apellis, Aviceda, Boehringer, EyePoint Pharmaceuticals, Genentech, Jenssen, Novartis, Ocular Therapeutix, Oculus, Opthea, Outlook, Regenxbio, Regeneron, Unity Biotechnology;
Consultant: 4DMT, Adverum, Apellis, EyePoint Pharmaceuticals, Genentech, Neurotech, Opthea, Perceive Bio, Regenxbio, Regeneron, Retina AI, Samsung, Unity Biotechnology.
Arshad Khanani, MD, MA, FASRS
Director, Clinical Research
Sierra Eye Associates
Reno, NV
Disclosures: Consultant: 4DMT, AbbVie, Adverum, Alcon, Amgen, Annexin, Annexon, Apellis Pharmaceuticals, Aviceda Therapeutics, Beacon Therapeutics, Boehringer Ingelheim, Clearside Biomedical, Complement Therapeutics, Exegenesis Bio, EyePoint Pharmaceuticals, Frontera Therapeutics, Genentech, Gyroscope Therapeutics, i-Lumen Scientific, Iveric Bio, Janssen Pharmaceuticals, Kodiak Sciences, Kriya Therapeutics, Kyowa Kirin, Nanoscope, Novartis, Ocular Therapeutix, Oculis, Ocuphire, OcuTerra, Olive BioPharma, Opthea, Oxular, Oxurion, Perfuse, Ray Therapeutics, Recens Medical, Regeneron Pharmaceuticals, Regenxbio, Revive, RevOpsis, Roche, Sanofi, Stealth BioTherapeutics, Thea Pharma, Unity Biotechnology, Vanotech, Vial;
Research support: 4DMT, Adverum, Alexion, Annexon, Apellis Pharmaceuticals, Aviceda Therapeutics, Eluminex Biosciences, EyePoint Pharmaceuticals, Exegenesis, Genentech, Gyroscope Therapeutics, Iveric Bio, Janssen, Kodiak, Kyowa Kirin, Neurotech, Ocular Therapeutix, Oxular, Regenxbio;
Stock options: Aviceda Therapeutics, Oculis, Opthea, Perfuse Therapeutics, PolyPhotonix, Recens Medical, RevOpsis, Vial;
Board of Directors: Oculis.
Faculty, Staff, and Planners’ Disclosures
PER® mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.